Localized Therapy in Early- and Intermediate-Stage HCC

Opinion
Video

Medical oncologists outline localized therapy options for patients with early- and intermediate-stage hepatocellular carcinoma.

MMM_TA_HCC_Seg02_Localized_1
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
      HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
      Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
      Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
      Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
      PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
      Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
      Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
      Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
      Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
      Multidisciplinary Care is ‘Incredibly Important’ for Managing GI Cancers
      Multidisciplinary Care is ‘Incredibly Important’ for Managing GI Cancers
      The Intricacies of Sequencing Immunotherapy in GI Cancers
      The Intricacies of Sequencing Immunotherapy in GI Cancers
      Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
      Radiation Therapy Does Not Improve Survival in Gastric/GEJ Cancers
      Durvalumab Plus FLOT May Not Significantly Increase AEs in Gastric Cancer
      Durvalumab Plus FLOT May Not Significantly Increase AEs in Gastric Cancer
      Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
      Bringing Immunotherapy to Earlier Stages of Gastric/GEJ Cancer
      Related Content
      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      Tim Cortese
      April 2nd 2025
      Article

      Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Tim Cortese
      March 31st 2025
      Article

      A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      Educating Patients and Clinicians on End-of-Life Care and Discussions

      Kelley A. Rone, DNP, RN, AGNP-c
      November 11th 2024
      Podcast

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

      Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

      Tim Cortese
      March 26th 2025
      Article

      The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

      Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

      Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer

      Roman Fabbricatore
      March 23rd 2025
      Article

      Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.